Pharmacotherapies in Dupuytren Disease: Current and Novel Strategies

J Hand Surg Am. 2023 Aug;48(8):810-821. doi: 10.1016/j.jhsa.2023.02.003. Epub 2023 Mar 17.


Dupuytren disease is a benign, progressive fibroproliferative disorder of the hands. To date, only one pharmacotherapy (clostridial collagenase) has been approved for use in Dupuytren disease. There is a great need for additional nonsurgical methods that can be used to either avoid the risks of invasive treatments or help minimize recurrence rates following treatment. A number of nonsurgical modalities have been discussed in the past and continue to appear in discussions among hand surgeons, despite highly variable and often poor or no long-term clinical data. This article reviews many of the pharmacotherapies discussed in the treatment of Dupuytren disease and novel therapies used in inflammation and fibrosis that offer potential treatment options.

Keywords: Collagenase; Dupuytren; TGF-beta; fibrosis; myofibroblast.

Publication types

  • Review
  • Research Support, N.I.H., Extramural

MeSH terms

  • Clostridium histolyticum
  • Dupuytren Contracture* / surgery
  • Humans
  • Injections, Intralesional
  • Microbial Collagenase / therapeutic use
  • Treatment Outcome


  • Microbial Collagenase